Log in
OTCMKTS:TRSSF

Terrascend Stock Forecast, Price & News

$4.54
-0.07 (-1.52 %)
(As of 09/17/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.49
Now: $4.54
$4.65
50-Day Range
$2.80
MA: $4.14
$4.85
52-Week Range
$1.19
Now: $4.54
$5.10
Volume157,523 shs
Average Volume110,566 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TerrAscend Corp., a biopharmaceutical and wellness company, engages in the cultivation, development, and sale of medical cannabis in Canada. The company offers its cannabis products under the Knüba Naturals brand. It also provides education and support programs to physicians and patients through health care professionals. The company was incorporated in 2017 and is based in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TRSSF
CUSIPN/A
CIKN/A
Phone855-837-7295

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$4.54
-0.07 (-1.52 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRSSF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRSSF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Terrascend (OTCMKTS:TRSSF) Frequently Asked Questions

How has Terrascend's stock been impacted by Coronavirus (COVID-19)?

Terrascend's stock was trading at $1.8277 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TRSSF stock has increased by 148.4% and is now trading at $4.54.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Terrascend?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Terrascend in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Terrascend
.

What price target have analysts set for TRSSF?

4 Wall Street analysts have issued 1 year price targets for Terrascend's shares. Their forecasts range from $5.50 to $6.50. On average, they anticipate Terrascend's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price.
View analysts' price targets for Terrascend
.

Are investors shorting Terrascend?

Terrascend saw a increase in short interest in August. As of August 31st, there was short interest totaling 454,000 shares, an increase of 78.6% from the August 15th total of 254,200 shares. Based on an average daily volume of 309,400 shares, the short-interest ratio is presently 1.5 days.
View Terrascend's Short Interest
.

Who are some of Terrascend's key competitors?

Who are Terrascend's key executives?

Terrascend's management team includes the following people:
  • Dr. Michael Nashat, Founder, CEO, COO & Director (Age 35)
  • Mr. Matthew J. Johnson, Pres
  • Mr. Adam Kozak, Chief Financial Officer
  • Mr. Alex Correia, VP of Corp. Affairs & Communications
  • Ms. Dawn Vanek-Mithra, Director of Marketing

What is Terrascend's stock symbol?

Terrascend trades on the OTCMKTS under the ticker symbol "TRSSF."

How do I buy shares of Terrascend?

Shares of TRSSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Terrascend's stock price today?

One share of TRSSF stock can currently be purchased for approximately $4.54.

What is Terrascend's official website?

The official website for Terrascend is www.terrascend.com.

How can I contact Terrascend?

The company can be reached via phone at 855-837-7295.

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.